Figures computed from official regulatory filings — .
Analysttarget 12.29 USD (+378%) · consensus 4.64/5 · 13 buy · 1 hold · 0 sell
Ownershipinsiders 8.23% · institutions 86.05% · short 23.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Perspective Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
213 buys51 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | Sell | $250.9K | SEC |
| Lantheus Alpha Therapy, LLC | Sell | $526.1K | Unusual size | SEC |
| Lantheus Alpha Therapy, LLC | Sell | $245.6K | SEC |
| Lantheus Alpha Therapy, LLC | Sell | $111.6K | SEC |
| Lantheus Alpha Therapy, LLC | Sell | $131.2K | SEC |
| Lantheus Holdings, Inc. | Sell | $111.6K | SEC |
| Lantheus Holdings, Inc. | Sell | $245.6K | SEC |
| Morich Frank | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Woods Lori Atrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Spoor Johan M.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Puhlmann Markus | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HENSON HEIDI | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hunt Jonathan Roberttrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Martinez Maria E | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Williamson Robert F IIItrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hunt Jonathan Roberttrack record | Buy | $22.3K | conv 53 | SEC |
| Williamson Robert F IIItrack record | Buy | $19.9K | conv 62 | SEC |
| Sendek Joel | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Martinez Maria E | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Woods Lori Atrack record | Buy | $50K | conv 62Cluster | SEC |
| Spoor Johan M.track record | Buy | $49.3K | conv 62Cluster | SEC |
| Williamson Robert F IIItrack record | Buy | $81.6K | conv 75ClusterUnusual size | SEC |
| Williamson Robert F IIItrack record | Buy | $50.4K | conv 67Cluster | SEC |
| Graham Juan | Buy | $75K | conv 97ClusterFirst in 12mo | SEC |
| Spoor Johan M.track record | Buy | $10.3K | conv 54Cluster | SEC |